Acute ST elevation myocardial infarction during intravenous immunoglobulin infusion.
Autor(es): Barsheshet Alon,Marai Ibrahim,Appel Shmulik,Zimlichman Eyal
Resumo: Intravenous immunoglobulin (IVIG) preparations are increasingly being used in the treatment of autoimmune disorders. This treatment is regarded as generally safe, and most of the adverse effects associated with IVIG administration are mild and transient. This paper reports a 72-year-old patient with known ischemic heart disease admitted for a Guillain-Barré syndrome variant, who developed acute ST elevation myocardial infarction (MI) during the first hours of IVIG infusion. The literature on acute MI during IVIG treatment is reviewed. Evaluation of each patient for cardiovascular risk prior to IVIG treatment is recommended as is the assessment of risk versus benefit. If IVIG is prescribed, we propose close monitoring and slow infusion rate.
Imprenta: Annals of the New York Academy of Sciences, v. 1110, p. 315-318, 2007
Identificador do objeto digital: 10.1196/annals.1423.033
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies
Data de publicação: 2007
